305 related articles for article (PubMed ID: 34538261)
1. Megaloblastic anemia-related iron overload and erythroid regulators: a case report.
Vallet N; Delaye JB; Ropert M; Foucault A; Ravalet N; Deriaz S; Chalopin T; Blasco H; Maillot F; Hérault O; Gyan E
J Med Case Rep; 2021 Sep; 15(1):463. PubMed ID: 34538261
[TBL] [Abstract][Full Text] [Related]
2. Hepcidin and Anemia: A Tight Relationship.
Pagani A; Nai A; Silvestri L; Camaschella C
Front Physiol; 2019; 10():1294. PubMed ID: 31649559
[TBL] [Abstract][Full Text] [Related]
3. [The characteristics of iron metabolism in B12-deficient anemias (an evaluation of the functional status of megaloblastic erythropoiesis)].
Berliner GB; Kheĭfets LM
Ter Arkh; 1994; 66(7):58-61. PubMed ID: 7985132
[TBL] [Abstract][Full Text] [Related]
4. Non-transferrin-bound serum iron (NTBI) in megaloblastic anemia: effect of vitamin B(12) treatment.
Gafter-Gvili A; Prokocimer M; Breuer W; Cabantchik IZ; Hershko C
Hematol J; 2004; 5(1):32-4. PubMed ID: 14745427
[TBL] [Abstract][Full Text] [Related]
5. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I.
Tamary H; Shalev H; Perez-Avraham G; Zoldan M; Levi I; Swinkels DW; Tanno T; Miller JL
Blood; 2008 Dec; 112(13):5241-4. PubMed ID: 18824595
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Putative Erythroid Regulators of Hepcidin in Mouse Models of Anemia.
Mirciov CS; Wilkins SJ; Dunn LA; Anderson GJ; Frazer DM
PLoS One; 2017; 12(1):e0171054. PubMed ID: 28135344
[TBL] [Abstract][Full Text] [Related]
7. A Novel ALAS2 Missense Mutation in Two Brothers With Iron Overload and Associated Alterations in Serum Hepcidin/Erythroferrone Levels.
Lira Zidanes A; Marchi G; Busti F; Marchetto A; Fermo E; Giorgetti A; Vianello A; Castagna A; Olivieri O; Bianchi P; Girelli D
Front Physiol; 2020; 11():581386. PubMed ID: 33281618
[TBL] [Abstract][Full Text] [Related]
8. Growth differentiation factor 15 in erythroid health and disease.
Tanno T; Noel P; Miller JL
Curr Opin Hematol; 2010 May; 17(3):184-90. PubMed ID: 20182355
[TBL] [Abstract][Full Text] [Related]
9. Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice.
Li H; Choesang T; Bao W; Chen H; Feola M; Garcia-Santos D; Li J; Sun S; Follenzi A; Pham P; Liu J; Zhang J; Ponka P; An X; Mohandas N; Fleming RE; Rivella S; Li G; Ginzburg YZ
Blood; 2017 Mar; 129(11):1514-1526. PubMed ID: 28151426
[TBL] [Abstract][Full Text] [Related]
10. The mutual control of iron and erythropoiesis.
Camaschella C; Pagani A; Nai A; Silvestri L
Int J Lab Hematol; 2016 May; 38 Suppl 1():20-6. PubMed ID: 27161430
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietic regulators of iron metabolism.
Ganz T
Free Radic Biol Med; 2019 Mar; 133():69-74. PubMed ID: 29981834
[TBL] [Abstract][Full Text] [Related]
12. [The role of erythroferrone in iron metabolism: From experimental results to pathogenesis].
Vallet N;
Rev Med Interne; 2018 Mar; 39(3):178-184. PubMed ID: 28666715
[TBL] [Abstract][Full Text] [Related]
13. The association between growth differentiation factor-15, erythroferrone, and iron status in thalassemic patients.
Youssry I; Samy RM; AbdelMohsen M; Salama NM
Pediatr Res; 2024 Mar; 95(4):1095-1100. PubMed ID: 37464096
[TBL] [Abstract][Full Text] [Related]
14. Neonatal hemochromatosis with εγδβ-thalassemia: a case report and analysis of serum iron regulators.
Tsuge M; Kodera A; Sumitomo H; Araki T; Yoshida R; Yasui K; Sato H; Washio Y; Washio K; Shigehara K; Yashiro M; Yagi T; Tsukahara H
BMC Pediatr; 2022 Oct; 22(1):622. PubMed ID: 36309641
[TBL] [Abstract][Full Text] [Related]
15. Megaloblastic anemia.
Castle WB
Postgrad Med; 1978 Oct; 64(4):117-22. PubMed ID: 704501
[TBL] [Abstract][Full Text] [Related]
16. Growth differentiation factor 15 is related to anemia and iron metabolism in heart allograft recipients and patients with chronic heart failure.
Przybyłowski P; Wasilewski G; Bachorzewska-Gajewska H; Golabek K; Dobrzycki S; Małyszko J
Transplant Proc; 2014 Oct; 46(8):2852-5. PubMed ID: 25380934
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of iron overload in myelodysplastic syndromes and other bone marrow failure syndromes].
Kobune M
Rinsho Ketsueki; 2020; 61(7):753-763. PubMed ID: 32759562
[TBL] [Abstract][Full Text] [Related]
18. [Effect of GDF15 on iron overloading and erythropoiesis].
Zhao YS; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):537-41. PubMed ID: 21518525
[TBL] [Abstract][Full Text] [Related]
19. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.
Kautz L; Jung G; Du X; Gabayan V; Chapman J; Nasoff M; Nemeth E; Ganz T
Blood; 2015 Oct; 126(17):2031-7. PubMed ID: 26276665
[TBL] [Abstract][Full Text] [Related]
20. Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II.
Casanovas G; Swinkels DW; Altamura S; Schwarz K; Laarakkers CM; Gross HJ; Wiesneth M; Heimpel H; Muckenthaler MU
J Mol Med (Berl); 2011 Aug; 89(8):811-6. PubMed ID: 21475976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
